Sign in
4

Changes in Ownership

Kymera Therapeutics, Inc. Filed Acc 0001415889-24-007890

Director sold 353,357 shares at an average $42.20 ($14,912,376)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Booth Bruce · Director

Table I: Non-derivative

12 lines
Date Transaction Shares Price Value Owned after D/I
2024-03-11 Sale : show line 1 in the form 10b5-1 −37,180 $42.77 $1,590,189 4,930,934 I
2024-03-11 Sale : show line 2 in the form 10b5-1 −5,122 $43.42 $222,397 4,925,812 I
2024-03-11 Sale : show line 3 in the form 10b5-1 −7,837 $42.77 $335,188 882,311 I
2024-03-11 Sale : show line 4 in the form 10b5-1 −1,045 $43.42 $45,374 881,266 I
2024-03-12 Sale : show line 5 in the form 10b5-1 −126,066 $41.94 $5,287,208 4,799,746 I
2024-03-12 Sale : show line 6 in the form 10b5-1 −8,581 $42.52 $364,864 4,791,165 I
2024-03-12 Sale : show line 7 in the form 10b5-1 −26,452 $41.94 $1,109,397 854,814 I
2024-03-12 Sale : show line 8 in the form 10b5-1 −1,819 $42.52 $77,344 852,995 I
Open-market sales · 353,357 sh · avg $42.20 · $14,912,376
Loading xslF345X05/form4-03132024_110328.xml…